Table 1.
Patient and transplant related characteristics.
| PTCy (n = 44) | ATG (n = 37) | P value | ||
|---|---|---|---|---|
| Median follow-up (months) [95% CI] | 12 [11.97–12.16] | 12 [11.93–12.3] | 0.19 | |
| Patient age (years) | median (min-max) [IQR] | 64.4 (36–71.1) [57.5–66.5] | 64.3 (21.3–70.7) [59.4–67.6] | 0.73 |
| Patient gender | male | 30 (68.2%) | 26 (70.3%) | 0.84 |
| female | 14 (31.8%) | 11 (29.7%) | ||
| Recipient cytomegalovirus serostatus | Negative | 19 (43.2%) | 17 (47.2%) | 0.29 |
| Positive | 25 (56.8%) | 17 (47.2%) | ||
| missing | 0 | 3 | ||
| ECOG | 0 | 25 (61%) | 19 (57.6%) | 0.78 |
| 1 | 15 (36.6%) | 12 (36.4%) | ||
| 2 | 1 (2.4%) | 2 (6.1%) | ||
| missing | 3 | 4 | ||
| Diagnosis | acute myeloid leukemia | 21 (47.7%) | 17 (45.9%) | 0.66 |
| acute lymphoblastic leukemia | 2 (4.5%) | 2 (5.4%) | ||
| multiple myeloma | 1 (2.3%) | 3 (8.1%) | ||
| lymphoma | 8 (18.2%) | 5 (13.5%) | ||
| chronic lymphocytic leukemia | 1 (2.3) | 0 (0%) | ||
| myelodysplastic syndrome | 8 (18.2%) | 8 (21.6%) | ||
| myeloproliferative disorder | 1 (2.3%) | 2 (5.4%) | ||
| other | 2 (4.5%) | 0 | ||
| Status at transplantation | diagnosis | 1 (2.3%) | 2 (5.4%) | 0.15 |
| CR1 | 29 (65.9%) | 17 (45.9%) | ||
| CR2 | 2 (4.5%) | 7 (18.9%) | ||
| CR3 | 4 (9.1%) | 2 (5.4%) | ||
| PR | 4 (9.1%) | 7 (18.9%) | ||
| R/R | 4 (9.1%) | 2 (5.4%) | ||
| Time randomization-conditioning regimen (days) | median (min-max) [IQR] | 7 (1–21) [2–9.5] | 7 (1–23) [2–10] | 0.72 |
| Year of transplant | median (min-max) | 2018 (2017–2019) | 2018 (2017–2019) | 0.54 |
| Donor | matched related | 17 (38.6%) | 15 (40.5%) | 0.86 |
| 10/10 matched unrelated | 27 (61.4%) | 22 (59.5%) | ||
| Donor sex | male | 23 (52.3%) | 21 (58.3%) | 0.59 |
| female | 21 (47.7%) | 15 (41.7%) | ||
| missing | 0 | 1 | ||
| Donor age (years) | median (min-max) [IQR] | 38 (18–69) [27–54.2] | 31 (21–69) [25–56] | 0.66 |
| missing | 2 | 2 | ||
| Donor cytomegalovirus serostatus | negative | 25 (58.1%) | 20 (57.1%) | 0.93 |
| positive | 18 (41.9%) | 15 (42.9%) | ||
| missing | 1 | 2 | ||
| Graft cell content | ||||
| CD34 × 10.6/Kg | median (min-max) [IQR] | 6 (1.5–11.1) [4.7–7.6] | 6.6 (2.6–10.9) [4.7–8.2] | 0.42 |
| missing | 1 | 1 | ||
| Associated IS | CsA +MMF | 28 (63.6%) | 24 (64.9%) | 0.91 |
| CsA alone | 16 (36.4%) | 13 (35.1%) |
CR complete remission, IS immunosuppressive drug, IQR interquartile range, PR partial response, R/R relapsed or refractory, PTCy post-transplant cyclophosphamide, ATG anti-thymocyte globulin, CsA cyclosporine A, MMF mycophenolate mofetil, ECOG Eastern Cooperative Oncology Group.